Introduction: Steroid sulfatase (STS) is an enzyme which cleaves sulfate groups from a variety of steroid hormones, thereby altering their activity and solubility. The expression and activity of STS is increased in female mammalian tissues (including brain) during late pregnancy and into the postpartum period. STS-deficient human and mouse mothers (as a consequence of genetic mutation or acute pharmacological manipulation) show evidence for elevated psychopathology and abnormal behaviour respectively in the postpartum period. In mice, these behavioural effects can be partially normalised through administration of the antipsychotic ziprasidone.
Introduction
Steroid sulfatase is an enzyme which cleaves sulfate groups from a variety of steroid hormones e.g. dehydroepiandrosterone sulfate (DHEAS), thereby altering their solubility and activity [Mueller et al., 2017] . STS is expressed in numerous mammalian tissues, with highest expression in the placenta [www.ncbi.nlm.nih.gov/unigene/] ; in the developing and adult human brain, relatively high STS expression and activity is seen in the cortex, thalamus, cerebellum, basal ganglia, hipocampus and hypothalamus [Stergiakouli et al., 2011; Perumal and Robins, 1973] . STS deficiency is associated with increased developmental and mood disorder risk and a number of behavioural differences including: inattention, increased impulsivity and altered mood and social function [Cavenagh et al., 2019; Chatterjee et al., 2016; ; these behavioural differences may be mediated, in part, by underlying changes in serotonergic or cholinergic function Rhodes et al., 1997] .
In both humans and rodents, STS expression and activity increases in brain and peripheral tissues towards the end of pregnancy and into the postpartum period; hence, enzyme deficiency or dysfunction could potentially be associated with postpartum psychopathology [Davies, 2018; Davies, 2012] . Consistent with this, we have recently shown that women who are heterozygous for genetic mutations encompassing STS are at increased risk of postpartum mood disorders [Cavenagh et al., 2019] . We have also demonstrated that female mice, in which STS activity is acutely, and systemically, inhibited with 667-Coumate shortly after giving birth, show altered maternal behaviour (specifically anxiety-related and startle phenotypes) relative to vehicle-treated mice; these drug-induced behavioural abnormalities can be partially reversed by concurrent administration of the atypical antipsychotic drug ziprasidone .
To investigate the neurobiology underlying the postpartum behaviour phenotypes in STS deficient individuals, we compared whole brain gene expression in behaviourally-defined 667-Coumate and vehicle-treated new mouse mothers. Given the large between-group behavioural differences, we suspected that screening by microarray would be able to readily identify robust gene expression differences and candidate biological pathways, and we reasoned that analysis of whole brain tissue would capture activity changes across multiple interacting brain regions.
Methods

Drug administration and behavioural analysis
Within 12hr of giving birth, female mice were injected with either 10mg/kg 667-Coumate or vehicle solution per os (n=12 per group); they were then injected with the same solution 48hr
later, and behaviourally-tested 12hr after that. Behavioural testing comprised of sequential assessment on the elevated plus maze, in a locomotor activity chamber, and in a startle/prepulse inhibition paradigm. A second batch of mice had 667-Coumate injections as described above, but also ziprasidone injections i.p. 24hr after giving birth, and 1hr prior to behavioural testing at doses of either 0, 0.3 or 1.0mg/kg (n=11, n=11 and n=7 respectively). 
Between
Tissue collection, RNA extraction and cDNA synthesis
3hr after behavioural testing, subjects were culled by cervical dislocation. Whole brains were immediately removed, bisected sagitally, and frozen on dry ice. High-quality total RNA was extracted from the right hemisphere of the brain using RNeasy Plus Universal Midi Kit (Qiagen) according to the manufacturer's instructions. For microarray analysis, three biological replicates per group were generated, with each replicate containing equal amounts of RNA pooled from four hemibrains; 260/280 absorbance ratios of 2.05-2.08 and RIN numbers of 9.4-9.8 were recorded for the six replicates using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). 20µl cDNA solution per hemibrain was synthesised from 4-5g RNA using RNA-to-cDNA EcoDry Premix with random primers (Clontech), and was diluted 50-fold with distilled water.
Microarray hybridisation and bioinformatic analysis
Microarray analysis was conducted by Central Biotechnology Services at Cardiff University according to standard protocols. Briefly, biotin-labelled targets for the microarray experiment were prepared using 100ng of total RNA per replicate. Sense single-stranded cDNA was synthesized, fragmented and labelled using the Genechip WT PLUS Reagent Kit (Affymetrix) in conjunction with the Affymetrix Genechip Poly-A RNA Control Kit as described in the User Manual (P/N 703174). A hybridization cocktail containing the biotinylated target was incubated with the GeneChip Mouse 2.0 ST array (Affymetrix) at 60rpm for 16hr at 45°C in a Genechip Hybridisation Oven 645. After hybridization, non-specifically bound material was removed by washing, and specifically-bound target was detected using the GeneChip Hybridization, Wash and Stain Kit, in conjunction with the GeneChip Fluidics Station 450 (Affymetrix). The arrays were scanned using a GeneChip Scanner 3000 7G (Affymetrix) in conjunction with Affymetrix Genechip Command Console (AGCC) software. Data were normalised using Robust Multiarray Average (RMA); the overall pattern of normalised expression data appeared equivalent across the six replicates. Differential gene expression analysis was performed using lmFit and eBayes from the Limma package [Sartor et al., 2006 ]. FDR-corrected and nominal p-values were generated for each probe, with values<0.05 being regarded as nominally statistically-significant. Pathway analysis was performed using Database for Annotation, Visualisation and Integrated Discovery version 6.8 (DAVID, RRID: SCR_001881) [Dennis et al., 2003] . Raw microarray data are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress, RRID: SCR_002964) under accession number E-MTAB-7233.
Quantitative Polymerase Chain Reaction (qPCR)
qPCR was performed using a Rotorgene 6000 coupled with a CAS1200 automated set-up, and utilizing standard consumables (Qiagen, Manchester, UK). PCR reactions were performed using 5μl cDNA mix and 200nM custom-designed primers ( Table 1) and SensiMix (Bioline, London, UK). qPCR data were analysed using ΔCt methods as described previously [Isles et al., 2004] with normalisation to the mean of three 'housekeeping gene standards' (Hprt, Gapdh and Rn18s) whose expression was significantly (p<0.001) correlated within the samples.
Groups were compared by either Mann-Whitney U test, unpaired t-test or One Way ANOVA. Table 1 . Primer sequences used for quantitative PCR analysis. Primers were designed to allow optimum amplification, to span intron-exon boundaries where possible, and to amplify key coding gene transcripts.
Gene
Forward primer 5'-3' Reverse primer 5'-3'
Results
Behavioural and endocrine comparison in animals used for microarray analysis
A subset of behaviourally-defined animals from Humby et al. (2016) 
Significantly-differentially expressed genes in the microarray analysis
We identified 1,081 unique differentially-expressed transcripts with a nominal p-value cut-off<0.05; the 24 most highly differentially expressed of these (fold change>1.5) are listed in Fpr2); for the 213 genes, the KEGG pathway 'olfactory transduction' remained highly significant (p=3.6x10 -11 ), as did the GO biological pathway terms 'G-protein-coupled receptor signalling' and 'sensory perception of smell' (p=7.9x10 -12 and p=1.2x10 -12 respectively) and the GO molecular function terms 'G-protein coupled receptor activity' and 'olfactory receptor activity' (p=9.6x10 -17 and 2.4x10 -13 respectively).
Quantitative PCR (qPCR)
qPCR analysis was performed for five of the most highly-differentially expressed genes from [Moura et al., 2016; Gammie et al., 2016] . Whilst the direction of expression difference was generally consistent across the microarray and qPCR analyses for these genes, only two genes (Cyp2g1 and Stoml3)
were significantly differentially-expressed according to qPCR (U=34.0, one-tailed p=0.014 and t[15.3]=-1.83, one-tailed p=0.04 respectively) (Figure 1) ; for the remaining four genes, p>0.075. We next tested whether Cyp2g1 and Stoml3 expression was sensitive to the coadministration of vehicle or ziprasidone (0.3mg/kg or 1.0mg/kg) in 667-Coumate treated animals; the expression of neither of these genes was affected: Cyp2g1 (F[2,28]=0. 58, p=0.57) and Stoml3 (F[2,28]=2.83, p=0.08) (Figure 2) . 
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Discussion
In this study we investigated whole brain gene expression signatures underlying abnormal maternal behaviour in a novel mouse model of postpartum mood disorder (STS inhibition with 667-Coumate). Although our vehicle and 667-Coumate treated groups differed substantially both in terms of their behaviour and with respect to a peripheral endocrine marker of STS inhibition (DHEAS:DHEA ratio), and the microarray experiment was performed with standard quality control procedures, we identified surprisingly few gene expression differences between the groups; those changes which we did identify by microarray were relatively small in magnitude and most could not be verified by quantitative PCR. These data indicate that, at least at the timepoint we assayed, large brain gene expression differences do not substantially contribute towards abnormal maternal behaviour in the STS inhibition mouse model, and suggest that the behavioural differences are associated with another underlying biological mechanism e.g. the aggregate effect of small expression changes across many genes. This idea is consistent with our previous observations of: a) few large, statistically-significant, gene expression differences between whole brain samples from male mice lacking the Sts gene and wildtype animals , despite considerable between-group behavioural differences Davies et al., 2009] and b) evidence that small brain expression changes (<1.5-fold) detectable between 667-Coumate and vehicle-treated mice by qPCR, but not detectable by the present microarray study, might be associated with postpartum behavioural phenotypes . We did not identify any overlap between genes significantly differentially expressed in the current study, and those whose expression was altered in whole brain from Stsdeficient male mice , and nor was there any overlap with genes whose skin expression was altered in male patients with steroid sulfatase deficiency [Hoppe et al., 2012] ;
hence, the genetic mechanisms associated with acute STS inhibition in females and constitutive STS deficiency in males are likely to be largely dissociable.
We did observe robust upregulation of the Cyp2g1 and Stoml3 genes (~3-fold and 1.5fold respectively) in 667-Coumate treated whole brain. The expression of both genes is restricted to the olfactory system in mice [Zhuo et al., 2004; Goldstein et al., 2003 ]. CYP2G1
is a major P450 enzyme in the olfactory mucosa of rodents, and, whilst its absence in homozygous knockout mice does not appear to impair olfaction, it does result in altered steroid hormone metabolism and metabolic activation of coumarin [Zhuo et al., 2004] .
Increased expression of Cyp2g1 following administration of 667-Coumate, a tricyclic coumarin sulfamate [Woo et al., 2000] , is perhaps, therefore, unsurprising, and further evidence that the drug is influencing neurophysiology. In man, functional Cyp2g1 orthologues appear to be rare [Sheng et al., 2000] . Whilst the biological roles of STOML3 remain to be fully clarified, there is some evidence that the protein mediates mechanosensory processes [Wetzel et al., 2007] . The elevated expression of Cyp2g1 and Stoml3 genes in 667-Coumate-treated mouse brain could not be reduced through antipsychotic (ziprasidone) adminstration, indicating that these genes and their asociated proteins are unlikely to play a large role in mediating the rescue effect of ziprasidone on aspects of maternal behaviour.
Pathway analysis incorporating all nominally-significant microarray hits (including those with low differential expression) suggested that 667-Coumate may perturb olfactory transduction processes and that this perturbation may mediate drug-induced effects on postpartum maternal behaviour in the mouse; potentially, the increased prevalence of postpartum mood disorder in STS deficient women may be partially attributable to abnormalities within the olfactory system and/or its links to the limbic system. This possibility is feasible in light of the clinical observation that 667-Coumate administration can elicit taste disturbances in female patients [Stanway et al., 2006] , and is consistent with an extensive literature on the importance of olfactory (and associated limbic) function in mammalian mothers [Corona and Levy, 2015] , with evidence that several steroid sulfates act as ligands within the mouse accessory olfactory system [Meeks et al., 2010] , with the expression of multiple olfactory receptors within human brain tissue [Flegel et al., 2013] , and with recent findings that olfactory processes are perturbed in a genetic mouse model of abnormal maternal behaviour [Creeth et al., 2018] and multiple mood disorders [Kamath et al., 2018] .
With regard to specific candidate genes of interest, both the study by Creeth et al. and the present study highlighted Olfr59 expression as being significantly upregulated (~1.4-fold, p<0.05) in hypothalamus and whole brain respectively in mothers with maternal behavioural abnormalities; this gene has no clear human orthologue.
The present study is limited in two main ways. First, we examined gene expression across the whole brain. Whilst this strategy is useful for capturing widespread expression changes and is sensible given our lack of knowledge about the underlying neuroanatomy of postpartum mood disorders, it is unlikely to detect gene expression changes between groups that are regionally-specific. Second, microarray technology, whilst cheap and easily implementable, is relatively insensitive to small gene expression changes, and has low resolution with regard to determining differentially expressed gene transcripts [Zhao et al., 2014] . Hence, future between-group comparisons might use a more specific, and more sensitive, technique such as RNA sequencing to assay gene expression in selected brain regions of importance to maternal behaviour and mood regulation, and whose chemistry is known to be altered by STS deficiency e.g. hippocampus.
